However, the PEMBRO-RT study found that PFS and OS in patients with PD-L1 high expression were shorter in the second-line immunotherapy combined with radiotherapy for lung cancer (23), also suggesting that the efficacy of biomarkers in multiline combined therapy involving PD1/PD-L1 blockade may be different from previous observations with immunotherapy alone. Here, CD274 is linked to lung carcinoma.